Prostate MRI characteristics in patients with inflammatory bowel disease.


Journal

European journal of radiology
ISSN: 1872-7727
Titre abrégé: Eur J Radiol
Pays: Ireland
ID NLM: 8106411

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 24 10 2020
revised: 18 12 2020
accepted: 22 12 2020
pubmed: 9 1 2021
medline: 15 4 2021
entrez: 8 1 2021
Statut: ppublish

Résumé

Previous studies have indicated an increased risk of prostate carcinoma (PCa) associated with inflammatory bowel disease (IBD). Prostate MRI of IBD patients could be expected to show a mixture of inflammation as well as higher than normal rates of PCa, which could impact interpretation and MRI performance. The purpose of this study is to evaluate the characteristics of prostate MRI in patients with IBD. 3140 patients with prostate MRI were evaluated. Coexisting IBD, PI-RADS score, and pathological results of prostate lesions (clinically significant PCa [csPCa]: Gleason score [GS] 7+, Non-csPCa: benign or GS 6) were assessed. The distribution of PI-RADS scoring and pathological result was assessed by chi-square test. 71 patients had IBD (IBD group), whereas the remaining 3069 patients did not (Non-IBD group). The proportion of abnormal MRI (PI-RADS 3, 4 or 5) was 51 % (36/71) in IBD group and 47 % (1436/3069) in Non-IBD groups (p = 0.513). Total of 1285 patients underwent biopsy or prostatectomy. The proportion of csPCa at pathology was 35 % (12/34) in IBD group and 56 % (699/1251) in non-IBD groups (p = 0.017). The positive predictive value of abnormal MRI for csPCa was significantly lower in IBD group (39 %, 19/31) compared to Non-IBD group (63 %, 657/1047) (p = 0.007). The proportion of csPCa at pathology and positive predictive value of abnormal MR for csPCa were lower in patients with IBD group compared to Non-IBD group.

Identifiants

pubmed: 33418382
pii: S0720-048X(20)30693-8
doi: 10.1016/j.ejrad.2020.109503
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109503

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Hiroaki Takahashi (H)

Mayo Clinic, Department of Radiology, Minnesota, USA.

Adam T Froemming (AT)

Mayo Clinic, Department of Radiology, Minnesota, USA.

David H Bruining (DH)

Mayo Clinic, Department of Gastroenterology and Hepatology, Minnesota, USA.

R Jeffrey Karnes (RJ)

Mayo Clinic, Department of Urology, Minnesota, USA.

Rafael E Jimenez (RE)

Mayo Clinic, Department of Anatomic Pathology, Minnesota, USA.

Naoki Takahashi (N)

Mayo Clinic, Department of Radiology, Minnesota, USA. Electronic address: Takahashi.Naoki@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH